Izotropic's IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose

Core Insights - Izotropic Corporation has integrated a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, making it the first system to offer real-time customized radiation dosing tailored to individual patient needs [1][2] - The global breast imaging device market is projected to grow from USD $5.4 billion in 2024 to USD $8.69 billion by 2030, driven by trends in personalized medicine and increasing breast cancer incidence [4] Company Developments - The optical pre-scan technology captures a radiation-free image of the breast to calculate a personalized radiation dose based on breast size, enhancing operational efficiency and patient comfort [2][3] - IzoView is advancing through the U.S. FDA's Pre-Market Approval process and is preparing to initiate a pivotal clinical study in the U.S. to support its market entry [5] Market Trends - The introduction of personalized radiation dosing aligns with a broader market shift towards personalized medicine, adapting screening protocols to individual risk factors such as breast density and family history [4] - The growth of the breast imaging market is supported by expanded reimbursement for supplemental screening and the adoption of technologies that enable individualized imaging protocols [4]